[1]曾小兵,朱长东,谢宝强.利拉鲁肽对首诊2型糖尿病患者血糖、血脂及T细胞亚群的影响[J].医学信息,2019,32(22):125-127.[doi:10.3969/j.issn.1006-1959.2019.22.041]
　ZENG Xiao-bing,ZHU Chang-dong,XIE Bao-qiang.Effect of Liraglutide on Blood Glucose,Blood Lipids and T cell Subsets in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2019,32(22):125-127.[doi:10.3969/j.issn.1006-1959.2019.22.041]
点击复制

利拉鲁肽对首诊2型糖尿病患者血糖、血脂及T细胞亚群的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年22期
页码:
125-127
栏目:
药物与临床
出版日期:
2019-11-15

文章信息/Info

Title:
Effect of Liraglutide on Blood Glucose,Blood Lipids and T cell Subsets in Patients with Type 2 Diabetes Mellitus
文章编号:
1006-1959（2019）22-0125-03
作者:
曾小兵; 朱长东; 谢宝强
（赣州市立医院内分泌科，江西 赣州 341000）
Author(s):
ZENG Xiao-bing; ZHU Chang-dong; XIE Bao-qiang
(Department of Endocrinology,Ganzhou Municipal Hospital,Ganzhou 341000,Jiangxi,China)
关键词:
2型糖尿病; 利拉鲁肽; CD4+T细胞亚群
Keywords:
Type 2 diabetes; Liraglutide; CD4+ T cell subset
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2019.22.041
文献标志码:
A
摘要:
目的 探讨利拉鲁肽治疗首诊超重或肥胖2型糖尿病患者的效果及其对T细胞亚群的影响。方法 选取2018年2月~2019年6月我院收治的72例确诊为2型糖尿病超重或肥胖患者，采用随机数字表法分为对照组和研究组，每组36例。对照组予以常规治疗，研究组在对照组基础上加用利拉鲁肽治疗，比较两组治疗前后血糖水平（FPG、BPG、HbA1c）、空腹胰岛素+C肽、餐后2h胰岛素+C肽水平、BMI、血脂（HDL-C、LDL-C、VLDL-C、TC、TG）以及CD4+、CD4+/CD8+水平。结果 治疗后，研究组FPG、BPG、HBA1c水平低于对照组（P＜0.05），空腹胰岛素、餐后2h胰岛素和空腹C肽、餐后2h C肽水平高于对照组（P＜0.05）；研究组BMI水平低于对照组（P＜0.05）；研究组TG、TC、LDL-C、VLDL-C水平低于对照组，HDL-C水平高于对照组（P＜0.05）；研究组CD4+、CD4+/CD8+高于对照组（P＜0.05）。结论 利拉鲁肽可调节CD4+T细胞亚群平衡，改善胰岛素β细胞功能并降低胰岛素抵抗，可更好控制2型糖尿病患者血糖水平，改善血脂水平，降低体质量。
Abstract:
Objective To investigate the effect of liraglutide in the treatment of patients with overweight or obesity type 2 diabetes and its effect on T cell subsets. Methods 72 patients with type 2 diabetes who were overweight or obese were enrolled in our hospital from February 2018 to June 2019. They were randomly divided into the control group and the study group, with 36 cases in each group. The control group received routine treatment. The study group was treated with liraglutide on the basis of the control group. The blood glucose levels (FPG, BPG, HbA1c), fasting insulin + C peptide, and postprandial 2h insulin + C peptide levels were compared before and after treatment, BMI, blood lipids (HDL-C, LDL-C, VLDL-C, TC, TG) and CD4+, CD4+/CD8+ levels. Results After treatment, the levels of FPG, BPG and HBA1c in the study group were lower than those in the control group (P<0.05). The levels of fasting insulin, 2h postprandial insulin and fasting C-peptide, and 2h C-peptide after meal were higher than those in the control group (P<0.05). The BMI level of the group was lower than that of the control group (P<0.05). The levels of TG, TC, LDL-C and VLDL-C in the study group were lower than those in the control group, and the HDL-C level was higher than that in the control group (P<0.05). The study group CD4+, CD4+/CD8+ was higher than the control group (P<0.05). Conclusion Liraglutide can regulate the balance of CD4+ T cell subsets, improve insulin β cell function and reduce insulin resistance, which can better control blood glucose levels, improve blood lipid levels and reduce body mass in patients with type 2 diabetes.

参考文献/References:

[1]Sujanitha V,Sivansuthan S,Selvakaran P,et al.Over-weight, obesity and chronic complications of diabetes mellitus in patients attending Diabetic Centre, Teaching Hospital, Jaffna, Sri Lanka[J].Ceylon Medical Journal,2015,60(3):94. [2]Laakso M,Kuusisto J.Insulin resistance and hyperglycaemia in cardiovascular disease development[J].Nature Reviews Endocrinology,2014,10(5):293-302. [3]Saad MJ,Santos A,Prada PO,et al.Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance[J].Physiology(Bethesda),2016,31(4):283-293. [4]Chen X,Zhang D,Chen X,et al.Oral administration of visceral adipose tissue antigens ameliorates metabolic disorders in mice and eleveates visceral adipose tissue-resident CD4+CD25+Foxp3+regulatory T cells[J].Vaccine,2017,35(35PtB):4412-4620. [5]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292-344. [6]周文敬,金京姬,吴英花,等.从对糖耐量正常人群分层探析β细胞功能和胰岛素抵抗的发生发展[J].中华内分泌代谢杂志,2017,33(9):741-744. [7]Quan W,Jo EK,Lee MS.Role of pancreatic β-cell death and inflammation in diabetes[J].Diabetes,Obesity and Metabolism,2013,15(3):141-151. [8]黄倩,刘婵,黄福常,等.利拉鲁肽治疗新诊断2型糖尿病患者的有效性及安全性[J].河北医药,2019,41(12):1821-1824. [9]饶利民,胡立春.利拉鲁肽治疗初发2型糖尿病效果观察[J].慢性病学杂志,2019,20(7):1047-1048. [10]曹洁.2型糖尿病辅助性T细胞17（Th17）与调节性T细胞（Treg）失衡与HOMA-IR、HOMA-β的相关性研究[D].山西医科大学,2019.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
　HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(22):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
　DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(22):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
　CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(22):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(22):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
　LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(22):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
　GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(22):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[7]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
　XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Journal of Medical Information,2022,35(22):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[8]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
　YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Journal of Medical Information,2022,35(22):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[9]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
　ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Journal of Medical Information,2022,35(22):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
[10]刘 静.利拉鲁肽联合基础胰岛素对初诊2型糖尿病合并肥胖患者 血糖控制及体质量指数的影响[J].医学信息,2018,31(13):137.[doi:10.3969/j.issn.1006-1959.2018.13.040]
　LIU Jing.Effect of Liraglutide Combined with Basal Insulin on Blood Glucose Control and Body Mass Index in Newly Diagnosed Type 2 Diabetes Patients with Obesity[J].Journal of Medical Information,2018,31(22):137.[doi:10.3969/j.issn.1006-1959.2018.13.040]
[11]王晓洲,吴仰帆,栾晓军.利拉鲁肽对肥胖T2DM患者促炎-抗炎系统及左心舒张功能的影响[J].医学信息,2021,34(22):145.[doi:10.3969/j.issn.1006-1959.2021.22.045]
　WANG Xiao-zhou,WU Yang-fan,LUAN Xiao-jun.Effects of Liraglutide on Pro-inflammatory-anti-inflammatory System and Left Ventricular Diastolic Function in Obese T2DM Patients[J].Journal of Medical Information,2021,34(22):145.[doi:10.3969/j.issn.1006-1959.2021.22.045]
[12]陶 蕾,张宏江,范中阳.利拉鲁肽联合胰岛素治疗肥胖2型糖尿病的疗效[J].医学信息,2021,34(23):99.[doi:10.3969/j.issn.1006-1959.2021.23.028]
　TAO Lei,ZHANG Hong-jiang,FAN Zhong-yang.Effect of Liraglutide Combined with Insulin in the Treatment of Obesity Type 2 Diabetes Mellitus[J].Journal of Medical Information,2021,34(22):99.[doi:10.3969/j.issn.1006-1959.2021.23.028]
[13]张 彤.利拉鲁肽联合胰岛素治疗新诊断肥胖2型糖尿病的临床疗效及安全性[J].医学信息,2022,35(05):159.[doi:10.3969/j.issn.1006-1959.2022.05.042]
　ZHANG Tong.Clinical Efficacy and Safety of Liraglutide Combined with Insulin in the Treatment of Newly Diagnosed Obese Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(22):159.[doi:10.3969/j.issn.1006-1959.2022.05.042]
[14]房 芳,于 宏.利拉鲁肽联合二甲双胍治疗2型糖尿病的疗效观察[J].医学信息,2022,35(16):141.[doi:10.3969/j.issn.1006-1959.2022.16.036]
　FANG Fang,YU Hong.Effect of Liraglutide Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(22):141.[doi:10.3969/j.issn.1006-1959.2022.16.036]

更新日期/Last Update: 2019-11-15